The Latest Breaking News from Merck

Deep-pocketed investors have adopted a bearish approach towards Merck Co (NYSE:MRK), and it's something market players shouldn't ignore. Our tracking of public options records at Benzinga unveiled this significant move today. The identity of these investors remains unknown, but such a substantial move in MRK usually suggests something big is…

Nvidia reported third-quarter profit that doubled — putting it near the top of the S&P 500's growth. But look for profit growth elsewhere.

Merck (NYSE:MRK), known as MSD outside of the United States and Canada, announced today positive topline results from the Phase 3 ZENITH study evaluating WINREVAIR (sotatercept-csrk) in adults with pulmonary arterial

Merck is playing defense against Summit Therapeutics with a $3.3 billion licensing deal announced Thursday for a cancer drug.

Despite Merck & Co.’s underperformance relative to the broader market over the past year, Wall Street analysts remain bullish about the stock’s prospects.

Merck spooked investors on Thursday with a guidance cut after sales of its diabetes drugs and HPV vaccine lagged third-quarter forecasts.

'We fear a second Trump term would be bad for business and the U.S. economy.'

These companies have faced setbacks, but I'm confident their stock prices will flourish once again.

More than 41,000 people in the U.S. died of pneumonia in 2022, according to the CDC.

"It is integrated into everything that we do," says Merck's chief information and digital officer Dave Williams.

Merck & Co. is projected to report its third-quarter earnings result at the end of this month, and analysts expect a double-digit profit dip.